Company

Menlo Therapeutics, Inc.

Redwood City, US-based developer of therapies for immuno-inflammatory conditions, built on proprietary drug platforms.

About

Menlo Therapeutics, Inc. develops therapies for immuno-inflammatory conditions through proprietary drug platforms and candidates, including the InhiBET BET inhibitor platform and candidates VYN201 and VYN202. Founded in 2003 and based in Redwood City, California, the company is at the Series C stage. Its latest funding was a PIPE round of USD 23.915 mn led by Access Industries, and it reported USD 501,000 in revenue for 2024.

2Funding rounds

14Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in